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Despite many years of potent antiretroviral therapy, latently infected cells and low levels of plasma virus have been
found to persist in HIV-infected patients. The factors influencing this persistence and their relative contributions have
not been fully elucidated and remain controversial. Here, we address these issues by developing and employing a
simple, but mechanistic viral dynamics model. The model has two novel features. First, it assumes that latently infected
T cells can undergo bystander proliferation without transitioning into active viral production. Second, it assumes that
the rate of latent cell activation decreases with time on antiretroviral therapy due to the activation and subsequent
loss of latently infected cells specific for common antigens, leaving behind cells that are successively less frequently
activated. Using the model, we examined the quantitative contributions of T cell bystander proliferation, latent cell
activation, and ongoing viral replication to the stability of the latent reservoir and persisting low-level viremia. Not
surprisingly, proliferation of latently infected cells helped maintain the latent reservoir in spite of loss of latent
infected cells through activation and death, and affected viral dynamics to an extent that depended on the magnitude
of latent cell activation. In the limit of zero latent cell activation, the latent cell pool and viral load became uncoupled.
However, as the activation rate increased, the plasma viral load could be maintained without depleting the latent
reservoir, even in the absence of viral replication. The influence of ongoing viral replication on the latent reservoir
remained insignificant for drug efficacies above the ‘‘critical efficacy’’ irrespective of the activation rate. However, for
lower drug efficacies viral replication enabled the stable maintenance of both the latent reservoir and the virus. Our
model and analysis methods provide a quantitative and qualitative framework for probing how different viral and host
factors contribute to the dynamics of the latent reservoir and the virus, offering new insights into the principal
determinants of their persistence.
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Introduction
Quantitative analysis of viral decay characteristics in HIV
patients during treatment with antiretroviral therapy (ART)
has suggested that the plasma viral load declines in at least
three distinct phases (Figure 1). After an initial shoulder
period, reﬂecting both the pharmacokinetic delay of the
drugs and the intracellular delay required for a newly
infected cell to start producing progeny virus [1,2], the viral
load drops exponentially by one to two orders of magnitude
during the ﬁrst two weeks of therapy (the ﬁrst phase). This
reﬂects rapid viral clearance and the turnover of short-lived
productively infected CD4
þ T lymphocytes with a half-life of
less than a day [1,3–5]. Then a slower, second phase of viral
decay becomes apparent, with a half-life of 1–4 wk [6],
reﬂecting contributions to plasma virus from a number of
sources [6] including populations of longer-lived HIV-
infected cells, such as infected macrophages [7], and infected
CD4
þ T cells in a lower state of activation that permit lower
levels of viral replication [8], and release of virus from tissue
sources such as virus reversibly bound to follicular dendritic
cells in the germinal centers of the peripheral lymphoid
tissue [9–11]. After several months of ART, plasma HIV-1
RNA in many patients decreases to lower than 50 copies/ml
plasma [6,12,13], the limit of detection of current clinical
assays. However, even in patients with suppression of viral
load of lower than 50 copies/ml for many years, a low level of
virus may persist in plasma and other bodily compartments,
such as semen, which can be detected by supersensitive assays
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Abbreviations: ART, antiretroviral therapy; PI, protease inhibitors; RT, reverse
transcriptase; d, death rate of productively infected CD4
þ T cells; x, deceleration
rate in the activation of latently infected cells; g, deceleration rate in the T cell
recovery; k, replenishment rate of target cells from their source; e, total combined
drug efficacy, where (1 e)¼(1 eRT)(1 ePI); /1, fraction of plasma virus produced
by long-lived infected cells at the pretreatment quasi–steady state; /2, contribution
of latently infected cells to the pretreatment quasi–steady state pool of
productively infected CD4
þ T cells; dL, death rate of latently infected cells; lM,
death rate of productively infected long-lived cells; ePI, drug efficacy of PIs, where 0
  ePI   1; eRT, drug efficacy of RT inhibitors, where 0   eRT   1; a, activation rate of
latently infected cells; amin, minimum activation rate of latently infected cells; c,
virion clearance rate from the plasma; d, death rate of CD4
þ T cells; dM, death rate
of long-lived cells; f, fraction of new viral infections resulting in latency; k, viral
infectivity to CD4
þ T cells; kM, viral infectivity to long-lived cells; L, latently infected
cells; M*, productively infected long-lived cells; M, long-lived cells; N, number of
virions produced during the average lifespan of T* (in vivo burst size); p, maximum
proliferation rate of CD4
þ T cells in their density-dependent logistic proliferation;
pbs, bystander proliferation rate of latently infected memory CD4
þ T cells; pM, virus
production rate from productively infected long-lived cells; ps, a subscript denoting
a pretreatment quasi–steady state value; r, net regeneration rate of latently
infected cells, where r ¼ pbs   dL; sM, production rate of long-lived cells from their
source; T*, productively infected CD4
þT cells; T, CD4
þT cells that are susceptible to
infection (target cells); T0, T cell concentration at the beginning of simulation (3 mo
after initiation of ART); Tmax, T cell density at which its proliferation shuts off; Tps,
pretreatment T cell concentration; Tsat, T cell concentration that T approaches as t
! ‘ under suppressive ART; V, total plasma viral load, where V ¼ VI þ VNI; VI,
infectious virus; VNI, noninfectious virus produced by the action of PIs
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phase with viral load of lower than 50 copies/ml corresponds
to the third phase of viral decay.
Despite extensive studies over the last ten years, the source
of this persistent viremia has not been fully elucidated and
remains controversial. One possibility is that ART therapy is
not fully suppressive and HIV continues to replicate [18],
possibly in sites that have poor drug penetration, i.e., in ‘‘drug
sanctuaries’’ [19]. Another possibility is that although therapy
is fully suppressive, HIV-1 establishes a state of latent
infection in resting memory CD4
þ T cells [20,21], and
continued viremia is caused by release of virus due to
activation of these latently infected cells [22,23]. Alterna-
tively, both continued replication and release from latent
stores contribute.
The decay characteristics of the latent reservoir and plasma
viremia in the third phase of viral decay remain subjects of
much debate [24]. Initial estimates of the decay half-life of the
latent reservoir ranged from 6 mo [25,26] to 44 mo [27,28],
which were calculated by assuming a homogeneous latent
reservoir exhibiting ﬁrst-order exponential decay kinetics.
However, recent studies by Strain et al. [29,30] have suggested
that the pool of latently infected cells contains heterogeneous
cell populations that decay at different rates. By measuring
the clearance of both HIV-1 DNA and cell-associated
infectivity, they estimated that during the ﬁrst year of
treatment the latent reservoir has a median half-life of 18
wk. However, during the subsequent 3 y of treatment, the
decay rate declined substantially to a median half-life of 58
wk [30], and moreover, this deceleration appeared to
continue.
Studies that focus on the dynamics of plasma HIV-1 RNA in
this range of ,50 copies/ml are rare. Dornadula et al. [14]
reported that in all 22 patients taking suppressive ART they
studied, HIV-1 RNA levels were lower than 50 copies/ml
(mean level, 17 copies/ml) in the peripheral blood plasma,
quantiﬁed using the supersensitive RT-PCR assay. Yerly et al.
[15] reported the persistence of viremia down to three HIV-1
RNA copies/ml in groups of patients who started ART during
acute or chronic infection. Di Mascio et al. [16], using the
supersensitive RT-PCR assay, investigated ﬁve patients who
were selected on the basis of having the greatest degree of
viral suppression (no viral blips, no incidents of intercurrent
illness, or noncompliance with therapy) among a larger group
of more than 80 patients with undetectable viral loads. In
three of the ﬁve patients, statistically signiﬁcant viral load
decays below 50 copies/ml were observed with a mean half-life
of 6 mo, whereas the other two patients did not exhibit any
signiﬁcant decay of plasma viral load. Recently, Cofﬁn and
coworkers developed a real-time PCR method to detect and
quantify HIV-1 RNA in plasma down to one copy. Using the
single-copy assay, they reported that in chronically infected
patients, detectable plasma viremia persisted at low levels (in
the range of 1–20 copies/ml) even after 7 y of suppressive
ART, with a decay half-life of 2 y or even longer (Cofﬁn J
(2006) Principles of HIV disease pathogenesis. Presentation at
the 13th Conference on Retroviruses and Opportunistic
Infections; February 5–8, 2006; Denver, Colorado, United
States). The factors inﬂuencing the decay kinetics of the
latent reservoir and plasma viremia and their relative
contributions are still not well-understood.
With an aim toward assessing the broader implications of
the maintenance or decay of viral reservoirs, we develop and
employ here a simple viral dynamics model describing
interactions among viruses, productively infected cells, and
latently infected cells. For model parameters and the
comparison of model predictions, we adopted data from
Strain et al. [30], where they analyzed the decay kinetics of the
latent reservoir in 27 patients who initiated treatment during
primary infection either before or less than 6 mo after
seroconversion. We aim to understand, from a quantitative
and integrated perspective, how different viral and host
factors may affect the decay characteristic of the latent
reservoir and plasma viremia. Our results offer a new
perspective into the principal determinants of the stable
maintenance of the latent reservoir and the virus.
Results
Mathematical Models
A mathematical model describing the production and
clearance of HIV-1 and latently infected cells during ART is
Figure 1. A Schematic Illustration of the Decay Dynamics of HIV-1 after
the Initiation of Highly Active ART
DOI: 10.1371/journal.pcbi.0020135.g001
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Synopsis
Antiretroviral therapy has greatly reduced the mortality of HIV-
infected patients. However, even after a decade of suppressive
therapy, low levels of virus and latent viral reservoirs persist.
Flushing out these reservoirs is a major hurdle that remains to be
overcome by anti-HIV therapy. Despite many years of extensive
studies, we still lack quantitative understanding of the factors that
maintain viral reservoirs and prevent a cure of HIV infection. In this
paper, Kim and Perelson develop a novel mathematical model that
incorporates the possibility that latently infected cells, like other
memory cells, undergo bystander proliferation without being
activated. Using the model, they show that T cell bystander
proliferation, combined with latent cell activation, enables the
stable maintenance of both the latent reservoir and the virus, even
in the absence of viral replication. Further, they show that the
influence of ongoing viral replication on maintaining the latent
reservoir remains relatively insignificant for a range of high drug
efficacies. Their results suggest that if the long-term persistence of
the latent reservoir results principally from the intrinsic stability of
CD4
þ T cell memory, increasing the potency of anti-HIV therapies
may not be sufficient to eradicate HIV.
Latent Reservoir PersistencedT=dt ¼ k   dT þ pTð1   T=TmaxÞ ð 1   eRTÞkVIT ð1Þ
dT =dt ¼ð 1   fÞð1   eRTÞkVIT þ aL   dT  ð2Þ
dL=dt ¼ fð1   eRTÞkVIT þ rL  aL ð3Þ
dM=dt ¼ sM   dMM  ð 1   eRTÞkMVIM ð4Þ
dM =dt ¼ð 1   eRTÞkMVIM   lMM  ð5Þ
dVI=dt ¼ð 1   ePIÞNdT  þð 1   ePIÞpMM   cVI ð6Þ
dVNI=dt ¼ ePINdT  þ ePIpMM   cVNI ð7Þ
As in previous mathematical models, which describe
various aspects of HIV-1 dynamics [1,6,31,32], this model
includes T representing CD4
þ T cells that are susceptible to
infection (target cells), T* productively infected cells, L
latently infected cells, M long-lived CD4
þ cells, M* produc-
tively infected long-lived cells, VI infectious virus, and VNI
noninfectious virus-produced by the action of protease
inhibitors (PIs), respectively. The total amount of virus V¼VI
þ VNI. The notion of long-lived infected cells was introduced
in [6]. Such cells may include macrophages and monocytes [7],
as well as resting CD4
þ T cells that become infected and
produce low levels of virus [8].
Target cells are replenished from their source (thymus) at
rate k, and die at rate dT. They are infected by virus, with
infectivity k, but reverse transcriptase (RT) inhibitors block
the viral infection with an efﬁcacy eRT (0   eRT   1, with eRT
¼1 being a perfect drug), reducing the infectivity by (1 eRT).
Target cells are also created by proliferation of existing cells,
presumably in a density-dependent manner with a slower
proliferation as their density gets high. Here this mechanism
was represented by a logistic function in which p is the
maximum proliferation rate and Tmax is the target cell density
at which proliferation shuts off. Productively infected cells
are produced by infection of target cells and by the activation
of latently infected cells at rate aL. Then they die at rate dT*
either from viral cytopathic effects or by host immune
response.
The formation of latently infected cells was modeled by
assuming a fraction, f, of viral infections of target cells results
in latency. They may also be created as a result of
proliferation of latently infected memory T cells, and die by
cell senescence or possibly by a low level of viral cytopathicity
or cytotoxic T lymphocyte–mediated killing if they express
viral proteins [33,34]. Thus, in this model we are examining
the consequences of the assumption that occasional pro-
liferation of (latently infected) memory T cells can occur and
that this proliferation does not induce the cell’s activation
into viral production. In mice cytokines, interferons released
during the course of an immune response can induce
memory T cells to undergo a single division irrespective of
their antigen speciﬁcity [35,36]. This type of ‘‘bystander’’
proliferation, which does not activate the cells into clonal
expansion, has been hypothesized to be a means by which
immunologic memory is maintained. If such proliferation
also occurs in human memory CD4
þ T cells and did not cause
the transition from latent to active infection, then it would
function to increase the stability of the latent reservoir [37].
This bystander proliferation is not the same as the clonal
expansion of latently infected memory T cells that could be
caused by interaction with antigen or other stimuli, and
hence is not modeled by Equation 1. We assume that any
stimulus strong enough to stimulate clonal expansion of
latently infected cells, such as appropriate recall antigens,
would activate them and thereby cause the transition from
latent to active infection. One may explicitly describe the
proliferation and death of latently infected cells by deﬁning
separate kinetic constants, for example, pbs for the rate of
bystander proliferation and dL for the rate of death of
latently infected cells. However, here we lumped these into a
single parameter, the regeneration rate constant (r), by
deﬁning r ¼ pbs   dL. Then r . 0( r , 0) indicates that the
net effect of proliferation and death is the generation
(clearance) of latently infected cells.
The activation of latently infected cells, which transforms
these cells into productively infected cells, functions to
decrease the size of the latent reservoir. Here the hetero-
geneity in the activation rate among latently infected cells
[29,30] can be modeled by assigning a non-uniform distribu-
tion, instead of a single ﬁxed value, to the activation rate
constant (a) [38]. Alternatively, one can model the net effect
of the heterogeneous cell activation instead of explicitly
assigning an arbitrary distribution to a. Because cells speciﬁc
for frequently encountered antigens will be preferentially
activated and quickly removed from the latent reservoir, the
population of latently infected cells will gradually shift
toward cells speciﬁc for increasingly rare antigens, resulting
in progressive deceleration in the average activation rate of
the latent reservoir. We implemented this mechanism by
assuming that the activation rate constant exponentially
decays in time from its initial value (a0) to a certain minimum
value amin (0   amin   a0), i.e., a¼(a0 amin)e
 xtþamin, where x
  0 is the deceleration rate constant.
The remainder of the model is fairly standard [1,6,39].
Long-lived cells are created by a constant source at rate sM,
and die with rate constant dM. They are infected by virus, with
a net infectivity (1   eRT)kM, yielding productively infected
long-lived cells, which die at rate lMM*. Virus particles are
generated from productively infected cells (T*) and produc-
tively infected long-lived cells (M*), where N is the number of
virions produced during the average lifespan of T* (the burst
size), and pM is the virus production rate by M*. Due to the
action of PIs with an efﬁcacy ePI, however, only a fraction, (1 
ePI), of the virions are infectious. The sum of infectious and
noninfectious virus particles (VI þ VNI) corresponds to the
total plasma viral load (V), a quantity typically monitored in a
clinical setting. Both types of virus particles are cleared from
the plasma with a rate constant c.
Parameter Constraints
Because T cell counts and viral loads in HIV-1–infected
patients generally change very slowly before ART is begun, it
is reasonable to assume that these and other related system
variables are at a quasi-steady state before treatment. This
condition then can be used to identify relations existing
among parameters and thus to limit the ranges of values
parameters can take. At pretreatment, quasi–steady state dT*/
dt¼(1 f)kVTþaL dT*¼0 and dV/dt¼NdT*þpMM* cV¼
0. Further, pMMps*/cVps (¼/1), where the subscript ps is used to
denote a pretreatment quasi–steady state value, correspond
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Latent Reservoir Persistenceto the fraction of plasma virus produced by long-lived
infected cells, and apsLps/dTps*( ¼ /2) corresponds to the
contribution of latently infected cells to the quasi–steady
state pool of productively infected cells. Note that /2 can be
expanded further, i.e., /2 ¼ apsLps/dTps* ¼ (dTps*   (1  
f)kVpsTps)/dTps* ¼ (NdTps*   (1   f)NkTpsVps)/NdTps*, to give
NdTps* ¼ ((1   f)/(1   /2))NkTpsVps. Then /1 becomes /1 ¼
pMMps*/cVps ¼ (cVps   NdTps*)/cVps ¼ (cVps   ((1   f)/(1  
/2))NkTpsVps)/cVps ¼ (c   ((1   f)/(1   /2))NkTps)/c, yielding the
following parameter constraint:
k ¼ð 1   /1Þð1   /2Þc=ð1   fÞNTps ð8Þ
where /1 and /2 have been estimated to be 0.01–0.07 and
,0.01, respectively [6], implying that k , c/NTps.
Model Reduction
By applying several clinically valid assumptions and
relations among the above variables and parameters, the
proposed model can be reformulated as follows: ﬁrst, after a
transient increase during the initial 4–8 wk of treatment,
overall CD4
þ T cell counts in patients on suppressive therapy
increase slowly [3,40,41]. Further, the proportion of produc-
tively infected cells in the peripheral blood CD4
þ T cell
population in patients on therapy is generally small ( 0.05%)
[21], with higher frequencies found in gut-associated lym-
phoid tissue [42–44]. Therefore, as a ﬁrst approximation, it
may be reasonable to assume that the concentration of target
cells (T) remains constant. Later, we will examine the case in
which T increases. If T ¼ constant ¼ T0, where T0 denotes a
quasi–steady state value of T that can differ from one patient
to the next depending on the parameters characteristic of the
virus and host, then Equation 1 can be ignored in the analysis.
Second, because of the limited contribution of long-lived
infected cells to plasma viral loads (1%–7% in patients before
treatment) [6,8], their contributions to new rounds of viral
infection and virus production in patients on therapy will be
ignored in the main text. In the Materials and Methods
section, we will detail the effects of including this population
in our analysis and also show by simulation that for viral loads
lower than 50 copies/ml long-lived infected cells still make a
small contribution to total virus. Thus, Equations 4 and 5 and
the terms containing pMM* in the Equations 6 and 7 will be
ignored in the subsequent analysis. Third, because V ¼ VI þ
VNI, the summation of Equations 6 and 7 leads to the equation
dV/dt ¼ NdT*   cV. Note that this equation can also be
obtained by substituting VI ¼ (1   ePI)V and VNI ¼ ePIV into
Equations 6 and 7, respectively. Before therapy, ePI¼0, V¼VI,
and VNI¼0, and thus the conditions VI¼(1 ePI)V and VNI¼
ePIV, are satisﬁed. Once therapy is begun (ePI 6¼ 0), although
these conditions are not satisﬁed initially, simulations show
that with typical parameters, after a few days the ratio of
infectious and noninfectious viruses approaches VI/VNI¼(1 
ePI)/ePI. Therefore, the condition VI ¼ (1   ePI)V should be
satisﬁed at the beginning of the third phase of viral decay,
and it can be substituted into the above differential equations
to express the system in terms of a measurable quantity V.
Finally, one can deﬁne a composite parameter e as (1 e)¼(1
 eRT)(1 ePI), and then e represents the total combined drug
efﬁcacy [31,45]. Below we analyze the resulting differential
equations:
da=dt ¼  xða   aminÞð 9Þ
dT  =dt ¼ð 1   fÞð1   eÞkT0V þ aL   dT   ð10Þ
dL=dt ¼ fð1   eÞkT0V þ rL  aL ð11Þ
dV=dt ¼ NdT   cV ð12Þ
Model Parameters
For the baseline CD4
þ T cell count before treatment (Tps),
we adopted the value, Tps¼486 cells/ll, from Strain et al. [30],
which was the median value for all 27 patients who initiated
treatment during primary infection either before (13 out of
27 patients) or less than 6 mo after seroconversion (14 out of
27 patients). While most primary infection patients are
identiﬁed after the viral peak, it is uncertain whether all
attained their viral set point. Nonetheless, this CD4
þ T cell
count is a reasonable pretreatment quasi–steady state value.
We assume that the third phase of viral decay (with viral load
below 50 copies/ml) began 3 mo after initiation of ART [29],
which corresponds to the initial time point of the proposed
model. By this time point, most viral replication should be
suppressed so that the latent pool should not be rapidly being
replenished any longer, allowing for the possibility of its
depletion. The CD4
þ T cell count at this time point (T0) was
calculated by assuming that CD4
þ T cells increased by 109
cells/ll during the ﬁrst 3 mo of ART [46], i.e., T0¼595/ll. The
concentration of latently infected cells at this time point was
calculated from Strain et al. [30], where the median value for
all the patients was slightly less than one infectious unit per
million cells ( 0.9 infectious unit per million). Because the
total number of CD4
þ T cells may be close to 1.2 3 10
11 cells
after the ﬁrst 3 mo of ART [47], we assumed that the total
number of latently infected cells with replication-competent
viral genomes at this time point (L0) was 10
5 cells. In the case
of the virus, assuming HIV distributes equally throughout the
body’s extracellular water, and that the typical 70-kg
individual has 15 l of extracellular water, then V0¼ 50 copies
of HIV-1 RNA/ml315,000 ml¼7.5310
5 HIV-1 RNA copies.
Other initial conditions of the proposed model, such as T0*
and a0, were chosen to match clinically observed decay
characteristics of the latent reservoir and the virus, which will
be discussed later.
The death rate of productively infected cells (d) and the
virion clearance rate (c) were set to our current best
estimates, d ¼ 1d
 1 [5] and c ¼ 23 d
 1 [48], respectively.
The in vivo burst size (N) is not well-known. Estimates based
on counting the number of HIV-1 RNA molecules in an
infected cell vary between 100 and a few thousands [49,50],
while estimates based on viral production have been as high
as 5 3 10
4 (Chen HY, Di Mascio M, Perelson A, Gettie A, Ho
D, et al. Determination of virus burst size in vivo using a
single-cycle SIV in rhesus macaques. Presentation at the 9th
Conference on Retroviruses and Opportunistic Infections;
February 24–28, 2002; Seattle, Washington, United States).
In our analysis, we chose N ¼ 2 3 10
4 HIV-1 RNA/cell as a
baseline value. For a standard three drug–therapy regime
containing one PI and two RT inhibitors, the total drug
efﬁcacy (e) was estimated to range from 0.68 to 0.75 [51],
and e ¼ 0.7 was applied as its baseline value. The fraction of
new viral infections resulting in latency (f) is not well-known,
but based on previous work [31] we chose f ¼ 3 3 10
 6 as a
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Latent Reservoir Persistencebaseline value such that there exist approximately ten
latently infected cells per million CD4
þ T cells at the
pretreatment quasi–steady state [30]. The viral infectivity (k)
was calculated using one of the above pretreatment steady
state conditions. Speciﬁcally, k ¼ (1   /1)c/(NTps) (obtained by
assuming f ’ 0 and /2 ’ 0 in Equation 8) was used as a
default since we felt the contribution of /1 (¼ 0.01   0.07) to
the value of k should not be ignored. For the given
parameter values, k ¼ 2.248 3 10
 6 ll (RNA copy)
 1 d
 1
when /1 ¼ 0.05. Although it has been estimated that
memory/effector cells (CD45RO
þ) have a half-life of 1–2
mo (or equivalently a decay rate of 0.012   0.023 d
 1) [52],
this rate represents the summation of their death and
activation rates, which are not necessarily the same as the
corresponding rates (dL and a) for latently infected cells.
Further, because several factors, including the reversion of
activated CD4
þ T cells to resting memory CD4
þ T cells and
the bystander proliferation of memory CD4
þ T cells (pbs),
contribute to the generation of memory CD4
þ T cells, even
if a steady state is assumed for the overall memory CD4
þ T
cell count [41], individual parameter values for pbs dL, and a
cannot be estimated. Therefore, we estimated a lumped
parameter r (¼ pbs   dL) and x, one of the parameters for a,
by nonlinear least-square ﬁtting of the proposed model to
relevant data, as will be explained below. Finally, unless
otherwise speciﬁed, the effects of viral evolution, which may
continuously change parameter values, and the possible cell
density–dependency of some parameters including d were
ignored [31,53].
Steady State Analyses
Steady states (or equilibrium points) of the proposed
system (Equations 9–12) can easily be found. In Materials and
Methods we examine the stability of the uninfected steady
state, i.e., [a ¯, T ¯*, L ¯, V ¯] ¼ [amin, 0, 0, 0], where overbars denote
steady state quantities, via eigenvalue analysis. In the special
case that the minimum activation rate of the latent reservoir
is zero (amin ¼ 0), the eigenvalues have the relatively simple
form (see Materials and Methods):
k1 ¼  x; k2 ¼ r;
k3;4 ¼ 
d þ c
2
6
1
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðd þ cÞ
2   4dðc  ð 1   fÞð1   eÞNkT0Þ
q
ð13Þ
In the special case of 100% effective therapy (e ¼ 1), the
eigenvalues of the system are
k1 ¼  x; k2 ¼ r   amin where amin   0 ðÞ ;
k3 ¼  c; and k4 ¼  d
ð14Þ
For the uninfected steady state to be (locally) stable, all the
eigenvalues should be negative. When amin ¼ 0, this requires
that x . 0 and r , 0 (i.e., the latently infected cell bystander
proliferation rate (pbs) is less than the death rate (dL)). Because
all the parameters are positive and f, e   1, (dþc)
2 4d(c (1
  f)(1   e)NkT0)   (d þ c)
2   4dc ¼ (d   c)
2   0, indicating that
both k3 and k4 are real, and that the eigenvalue with the
negative square root term (k3) is negative. Lastly, k4 , 0i s
satisﬁed if c . (1 f)(1 e)NkT0, or equivalently e . ec, where
the critical efﬁcacy [31,32] is
ec ¼ 1   c=ðð1   fÞNkT0Þð 15Þ
Because the reproductive number (R) for this system,
which represents the average number of secondary infected
cells produced by a single infected cell [54], corresponds to
R ¼ (1   f)(1   e)NkT0/c, this condition can also be expressed
as R , 1. Because a monotonically approaches amin (  0) as t
increases, the system approaches a linear system as t
increases, implying that no asymptotically stable nontrivial
periodic orbit exists, and thus the satisfaction of these
stability conditions also guarantees the global (asymptotic)
stability of the steady state. Therefore, the last condition
implies that given amin ¼ 0, x . 0 and r , 0, if clearance of
the virus in its host is fast enough, or therapy is effective
enough, the latent reservoir and the virus are predicted
eventually to be cleared from its host. That this is not
observed suggests that we should focus on the condition
under which the uninfected state is unstable.
The stability of the uninfected steady state is changed, or
equivalently a bifurcation occurs, when any of the eigenval-
ues (or their real parts when they are complex numbers)
becomes zero. Typically a manifold of equilibria other than
the steady state at the origin exists at this point, thereby
allowing for the possibility of the stable maintenance of the
latent reservoir and the virus at ﬁnite positive values. For
example, when the magnitude of the minimum activation
rate of the latent reservoir is zero (amin ¼ 0), from Equation
13 an eigenvalue becomes zero if x ¼ 0, r ¼ 0, or c ¼ (1   f)(1
  e)NkT0 (or equivalently R ¼ 1). Because a approaches zero
as t increases (Equation 9), the steady state condition of
Equations 10–12 becomes (1   f)(1   e)kT0V   dT* ¼ 0, f(1  
e)kT0V þ rL ¼ 0, and NdT*   cV ¼ 0, respectively. If c ¼ (1  
f)(1   e)NkT0, the ﬁrst and third equations above become
identical, implying that steady states with positive values of
productively infected cells and plasma virus (T* . 0 and V
. 0) satisfying the relation NdT*   cV ¼ 0 exist. The second
equation, L ¼ f(1   e)kT0V/( r) implies that for a positive
steady state value of V, the level of latently infected cells (L)
has a ﬁnite positive value if r , 0, i.e., their death rate (dL)i s
greater than the bystander proliferation rate (pbs). If this
were not the case, then latently infected cells would
continuously expand.
In general, when amin   0 (for 0   e   1), the bifurcation
condition of the system becomes (see Materials and Methods
for a detailed derivation):
rðð1   fÞð1   eÞNkT0   cÞþaminðc  ð 1   eÞNkT0Þ¼0 ð16Þ
This can be used to derive a more general form of the
critical efﬁcacy, i.e.,
ec ¼ 1  
cðr   aminÞ
rð1   fÞ amin ½  NkT0
ð17Þ
However, since f   1, this critical efﬁcacy essentially
reduces to ec ¼1   c/(NkT0), equivalent to Equation 15 when f
  1. If we use the pretreatment steady state condition NkTps¼
(1 /1)c, the critical efﬁcacy becomes ec¼1 Tps(r amin)/((1 
/1)[r(1   f)   amin]T0) ; 1   Tps/((1   /1)T0). This suggests the
critical efﬁcacy depends on patient-dependent parameters
(i.e., the fraction of viral production by long-lived cells (/1),
and the ratio of the pretreatment CD4
þ T cell count (Tps)t o
the CD4
þ T cell count at the beginning of the third phase of
viral decay (T0)). Note that in the calculations above, T0 is also
the T cell count at the uninfected steady state. Because in this
initial calculation we have assumed the T cell count does not
vary, T0 is in fact an underestimate of the T cell count that
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occurred. Thus, the critical efﬁcacy calculated above is lower
than previous estimates [31,32], which replace T0 by the T cell
count of a healthy individual.
Once parameters pass through the bifurcation condition,
the uninfected steady state becomes unstable. The implica-
tions of this instability will be discussed later.
These steady state analyses give the insights into long-term
behavior of the proposed system, and also provide necessary
conditions to maintain low, but nonzero steady state levels of
the latent reservoir and the virus under drug therapy.
However, they cannot provide much insight into dynamic
characteristics of the system, including decay proﬁles of the
latent reservoir and the virus, and the time required to reach
a steady state. In the following sections, we shall examine
dynamic behavior of the system.
Decay Kinetics Data of Latent Reservoir and Estimation of
Model Parameters
We ﬁrst consider data on the decay kinetics of the latent
reservoir. Strain et al. [30] studied HIV-1–infected patients
who initiated treatment during primary infection. They
estimated that the latent reservoir has a median decay half-
life of 18 wk during the ﬁrst year of treatment (weeks 4–48),
followed by a slower decay with a median half-life of 58 wk
during the subsequent three years of treatment. To make
progress with our analysis, we assumed that this group of
patients exhibited the greatest degree of decay of the latent
reservoir, based on this decay half-life, compared with other
studies with a half-life of 6–44 mo [25–28], and the time
interval after initiation of ART to reach viral load below 50
copies/ml (4–12 wk [29,30]), compared with 3–6 mo in other
studies [26,55]. We call this the maximal decay proﬁle of the
latent reservoir. Although ART might not completely stop
ongoing virus replication in this case, for simplicity we
assumed e ’ 1, implying that the decay proﬁle of the latent
reservoir was determined entirely by the relative contribu-
tions of the effects of cell activation (a) and cell regeneration
(r). Therefore we employed Equations 9–12 with e ¼ 1 as the
system model to explain the above data. The effect of ongoing
virus replication (e , 1) will be discussed later.
For dynamic simulations of the model, the initial
conditions (at 3 mo after initiation of ART) were chosen
as described in Materials and Methods. The parameters amin,
x, and r also need to be speciﬁed. For simplicity, we assume
here that amin ¼ 0. The effect of amin . 0 (or the persistence
of low-level activation of the latent reservoir) will be
discussed later. The remaining parameters, x and r, were
estimated by nonlinear least-square ﬁtting of the model
(speciﬁcally ln(L)) to the latent reservoir decay (speciﬁcally
ln(L
data)). Here the decay kinetics data (L
data) were generated
by using the median decay slopes of the latent reservoir for
all 27 patients in Strain et al. [30], under the assumption
that the third phase of viral decay began at 3 mo (13 wk)
after initiation of ART and that each phase of latent
reservoir decay (weeks 13–48 and subsequent three years)
exhibited exponential decay kinetics. For example, we
applied the following formula to mimic the Strain data:
for 0   t   t1, L
data ¼ L0exp(kd1t), and for t . t1, L
data ¼
L0exp(kd1t1)exp(kd2(t   t1)), where t1 ¼ (48–13) wk, kd1¼  0.038
/week (t1/2 ’ 18 weeks), and kd2 ¼  0.012 /week (t1/2 ’ 58
weeks). The data (open circles) and the best-ﬁt curve
generated from the model are shown in Figure 2A; the
corresponding parameter estimates are r ¼  0.00171 (6
0.00007, 95% CI) d
 1 and x ¼ 0.00939 (6 0.00064, 95% CI)
d
 1.I famin . 0, a approaches amin (Equation 9) and thus dL/dt
approaches dL/dt ¼ (r   amin)L (Equation 11) as t increases.
Therefore, the estimate of r in this case may be closer to
 0.00171 þ amin, or equivalently r   amin ’  0.00171 d
 1.
These are consistent with the result from the steady state
analysis that indicated that in order for the level of the
latent reservoir to approach zero, r , amin should be
satisﬁed. If e , 1, the estimate of r will be less than  0.00171
þ amin due to the contribution from ongoing viral
replication (f(1   e)kT0V). To examine this, we set e ¼ 0.7,
kept x ﬁxed at its estimated value, and found that with amin
¼ 0, the best-ﬁt value of r ¼  0.00205 d
 1. Further, the
increased viral replication, which can also be achieved by
increasing amin, enhanced the ﬁt of the theoretical curve to
the data during the early decay phase (unpublished data).
Decay Characteristics of Latent Reservoir and Virus
without Ongoing Viral Replication
We next investigated how the decay proﬁles of the latent
reservoir and plasma virus may be affected by variations in
parameters. We specially focused on examining the possi-
bility of maintaining plasma virus at a low, but nonzero
steady state level solely by activation of latently infected
cells (without any contribution from ongoing viral repli-
cation, i.e., e ¼ 1) without severely depleting the latent
reservoir. The steady state analysis (Equation 14) suggests
that the regeneration rate of latently infected cells (r)i sa
unique parameter that can change the stability of the
uninfected steady state, and that its stability changes at r ¼
amin when x . 0, allowing for the possibility of the stable
maintenance of the latent reservoir and the virus at nonzero
steady states. To check the possibility, we computed the time
proﬁles of both the latent reservoir and viral load when r ¼
amin ¼ 0 and x was maintained at its estimated value (x ¼
0.00939 d
 1). As shown in Figure 2B, the latent reservoir
approaches and stays at a nonzero steady state. However, the
viral load approaches zero (Figure 2B). The same was true
even when we increased r beyond its bifurcation value (r ¼
amin ¼ 0). For example, when r ¼ 0.0008 d
 1, the level of the
latent reservoir blew up (Figure 2A), while viral load kept
approaching zero (Figure 2B). These can be explained as
follows: because x . 0 and amin ¼ 0, a approaches zero as t
increases (Equation 9). Hence dT*/dt becomes dT*/dt ¼  dT*
as t increases (Equation 10), and thus T* and the production
of virus approaches zero as t ! ‘, leading to V ! 0a st !
‘. However, under this condition dL/dt becomes dL/dt ¼ rL as
t increases (Equation 11). Therefore, the latent reservoir can
either reach a nonzero steady state level (r ¼ 0) or blow up (r
. 0), while the virus is always eliminated. Note that although
we assumed a constant positive r value (r ¼ 0.0008 d
 1) for
the case with r . 0, the regeneration rate of latently
infected cells should decrease as CD4
þ Tc e l lc o u n t s
increase, causing the driving force for bystander prolifer-
ation to diminish. Therefore, the level of the latent reservoir
would be expected to reach a stable steady state instead of
blowing up as observed in Figure 2A.
These results suggest that if the magnitude of the minimum
activation rate of the latent reservoir is (or is close to) zero
(amin ’ 0), the stable maintenance of viral load at a nonzero
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Latent Reservoir PersistenceFigure 2. Effect of the Bystander Proliferation of the Latent Reservoir on the Latent Reservoir and on Plasma Viral Load
When there is no ongoing viral replication (e¼1) and the minimum activation rate of the latent reservoir is zero (amin¼0). The open circles indicate the
decay kinetics of the latent reservoir suggested by Strain et al. [30], where they found t1/2 ’ 18 wk up to week 35 and t1/2 ’ 58 wk for the subsequent 3
y. The solid curve with r ¼  0.00171 d
 1 and x ¼ 0.00939 d
 1 represents the best-fit curve to the data.
(A) Latent reservoir.
(B) Plasma viral load.
DOI: 10.1371/journal.pcbi.0020135.g002
PLoS Computational Biology | www.ploscompbiol.org October 2006 | Volume 2 | Issue 10 | e135 1238
Latent Reservoir Persistencesteady state level cannot be achieved without ongoing viral
replication. However, several genetic analyses have demon-
strated that in patients under ART with viral loads below 50
copies/ml, at least some portion of the viruses have genetic
sequences similar to those found in integrated provirus in
resting memory CD4
þ T cells which were infected prior to
ART [22,56–58]. This suggests that these plasma viruses
originated from the latent reservoir and that activation of
latently infected cells may be occurring in these patients (amin
. 0).
Effect of Persistence of Low-Level Activation of the Latent
Reservoir (when e ¼ 1)
As a next step, we examined whether the persistence of
low-level activation of the latent reservoir (amin . 0) would
enable maintenance of both the latent reservoir and plasma
virus at nonzero steady state levels without any contribution
from ongoing viral replication. To check the possibility, we
numerically solved the model, Equations 9–12, for amin ¼ 0,
a0/3, and a0/2, with x ﬁxed at its previously estimated value
(x ¼ 0.00939 d
 1), and for amin ¼ a0 (an upper extreme, when
x ¼ 0), at the bifurcation condition r ¼ amin (where the
stability of the uninfected steady state is changed). Figure 3
shows that if amin is large enough, both the latent reservoir
and plasma virus can reach nonzero steady states with non-
negligible magnitudes within the time period of interest.
Thus, if low-level activation of the latent reservoir persists
with a non-negligible magnitude, the viral load can be stably
maintained at a ﬁnite positive value without severely
depleting the latent reservoir, and without any contribution
from ongoing viral replication, as long as r (¼ pbs   dL) ’ amin
. 0. Therefore, amin itself can be a major factor inﬂuencing
the persistence of the latent reservoir and the virus.
Effect of Ongoing Viral Replication on the Decay
Characteristics of the Latent Reservoir and the Virus
We next investigated how variations in the drug efﬁcacy (e)
and the resulting variations in the extent of ongoing viral
replication affect the decay dynamics of the latent reservoir
and plasma virus. For simplicity, we consider the case of zero
minimum activation of the latent reservoir (amin ¼ 0), where
the stability of the uninfected steady state is changed at e¼ec
¼ 1   c/((1   f)NkT0). Using the given parameter values (Tps ¼
486/ll, /1¼0.05, f¼3310
 6, and T0¼595/ll), ec¼0.1402. As
noted above, because we are assuming T is constant, this value
of ec is artiﬁcially low. The critical efﬁcacy is increased if T0 is
increased, or if T rather than being constant increases with
time on therapy [46,59]. Clearly, if more target cells are
available, it becomes more difﬁcult to slow or halt viral
replication.
We computed the time proﬁles of both the latent
reservoir and plasma virus for e values above, at, and
slightly below the critical efﬁcacy, while x and r were
maintained at their previously estimated values, i.e., r ¼
 0.00171 d
 1 and x ¼ 0.00939 d
 1. As expected, for e . ec,
both the latent reservoir and the virus decay toward zero
(Figure 4A and 4B). When e ¼ ec, the viral load stays at a
nonzero steady state (Figure 4B). However, although the
latent cell population will ultimately reach a nonzero steady
state value, L ¼ f(1   e)kT0V/( r), since r ¼  0.00171 , 0;
nevertheless, L kept decreasing for at least ten years
(unpublished data), consistent with the decay observed by
Siliciano et al. [28,60]. When e was reduced to slightly below
the critical efﬁcacy, the viral load kept increasing (Figure
4B). Although the latent reservoir initially decayed, it
ultimately increased as the viral load increased and ﬁnally
blew up. These blow-ups occur because we have assumed the
target cell level is constant, thus there are always more cells
to infect. When target cells are limited, this behavior is
prohibited. For example, if the equation dT/dt ¼ k   dT þ
pT(1   T/Tmax)   (1   e)kVT (¼ f(T,V)), obtained by
substituting VI ¼ (1   ePI)V into Equation 1, is added to
the current model, then, as studied elsewhere [31,32],
instead of blowing-up, an infected steady state is reached
in which V ¯ ¼ k/((1   e)kT ¯) þ (p(1   T ¯/Tmax)   d)/((1   e)k).
To better understand the contribution of ongoing viral
replication to the level of the latent reservoir, we computed
Ra ¼j f(1   e)kT0V/(r   a)Lj, i.e., the ratio between the rate of
production of latently infected cells by ongoing viral
replication and the net removal rate of latently infected
cells (since r ¼  0.00171 , 0 and a   0). Here, Ra ¼ 1
indicates that the generation of latently infected cells equals
its clearance, and thereby leads to a steady state of the latent
reservoir if Ra is maintained at 1 as t increases. As shown in
Figure 4C, when e . ec, i.e., e ¼ 0.7, the rate of virus-induced
production of latently infected cells remained less than
0.0002% of its net clearance rate (or Ra , 2 3 10
 6)
throughout the entire time course, leading to a rapid decay
of the latent reservoir (Figure 4A). When e ¼ ec, Ra increased
the level the latent reservoir (L) decreased, and the viral
load (V) was constant. Nevertheless, Ra remained below 1,
even after 10 y of ART (unpublished data), implying that a
steady state of the latent reservoir was not reached within
this time period. It was the same even when a higher
fraction of viral infection resulting in latency (f)w a s
assumed, for example, its potential maximum value f ¼
0.05 [61] (and ec ¼ 0.095). When e , ec, i.e., e ¼ 0.133, Ra
increased more rapidly and passed through 1 as the viral
load increased.
These results suggest that for e   ec the contribution of
ongoing viral replication to the level of the latent reservoir
remains insigniﬁcant. However, under the condition (r   amin
, 0), where the level of the latent reservoir would approach
zero if there were not any ongoing viral replication, such as
for the group of patients considered here with r   amin ’
 0.00171 d
 1, ongoing viral replication may function to
maintain both the latent reservoir and the virus at nonzero
steady state levels. Further, e , ec may serve as a necessary
condition for their persistence, although the extent of
ongoing viral replication at ec itself may not be enough to
achieve the stable maintenance of the latent reservoir.
Finally, we also found that as the fraction of infection events
that lead to latency (f) increases, at the corresponding critical
efﬁcacy, the time to reach the steady state of the latent
reservoir is reduced, increasing the possibility of its stable
maintenance (unpublished data).
Although these studies could be extended further to
include parameter sensitivity analyses, as studied elsewhere
[62,63], given our intended focus and the limited space, we
chose not to elaborate on this point.
Effect of Variations in x
We also examined the role that variations in x play.
Because the eigenvalues of the system except k1 ¼  x do not
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the steady states of the system and its stability, but it simply
affects the kinetics of the system. For example, an increase
in x generally increases the level of the latent reservoir
before its steady state is reached by reducing its loss caused
by activation. Conversely, the viral load is transiently
reduced due to a reduced generation of productively
infected cells, suggesting that any variation in x transiently
drives the level of the latent reservoir and the viral load in
opposite directions before their steady states are reached.
Figure 3. Effect of Persistent Low-Level Activation of the Latent Reservoir on the Latent Reservoir and on Plasma Viral Load
When there is no ongoing viral replication (e¼1) and the rate of bystander proliferation of the latent reservoir is equal to the minimum activation rate (r
¼ amin), i.e., at the bifurcation condition.
(A) Latent reservoir.
(B) Plasma viral load.
DOI: 10.1371/journal.pcbi.0020135.g003
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Latent Reservoir and Virus
During ART, CD4
þ T cells increase but with a rate of
increase that tends to slow as the duration of therapy
increases [46,59]. Using the equation dT/dt ¼ k   dT þ pT(1  
T/Tmax)   (1   e)kVT, a modiﬁed form of Equation 1, the
dynamics of T cell recovery can be modeled. While this
equation, and forms with p¼0, have been commonly written,
it is not at all clear that this is a good model for CD4
þ T cell
recovery under ART. Independent of the value of p, this
model typically yields a strong predator–prey type oscillation
between virus (V) and T cells (T) instead of the monotonic
increase in the T cell concentration observed in most HIV
patients under suppressive therapy. Further, model parame-
ters, such as k and d, have been estimated for healthy
individuals, and thus they may not be reliable estimates to
describe the T cell recovery in HIV patients, especially for
patients with signiﬁcantly impaired thymic functions. Thus,
we decided to follow an approach introduced by Perelson et
al. [1] where the empirical data on CD4
þ T cell recovery was
used rather than the modiﬁed Equation 1. Thus, we modeled
the recovery of T cells and its progressive deceleration by
assuming the following saturation kinetics:
dT=dt¼gðTsat   TÞ; or; equivalently; T¼Tsat  ð Tsat   T0Þe gt
ð18Þ
where g ( 0) is a rate constant characterizing the extent of
deceleration of T cell recovery, and Tsat is the T cell
concentration that T approaches as t ! ‘. Here a theoretical
maximum value of Tsat is the CD4
þ T cell count observed in
HIV-negative individuals (’800–1,200 cells/ll [64–66]). Add-
ing Equation 18 to Equations 9–12 with T0 replaced by T in
Equations 10 and 11 gives an extended system with the
following uninfected steady state: [T ¯, a ¯, T ¯*, L ¯, V ¯]¼[Tsat, amin,0 ,
0, 0]. The Jacobian matrix evaluated at this steady state is
 g 00 0 0
0  x 00 0
00  d amin ð1   fÞð1   eÞkTsat
000 r   amin fð1   eÞkTsat
00 Nd 0  c
2
6 6 6 6 4
3
7 7 7 7 5
ð19Þ
Two of the eigenvalues of this Jacobian are g and x. The
other eigenvalues are given by Equation 20 in Materials and
Methods, with T0 replaced by Tsat. This suggests that all the
results obtained previously should remain qualitatively the
same except that a bifurcation now occurs at a condition
based on the value of Tsat instead of T0. For example, when
amin ¼ 0, the critical efﬁcacy of this system is ec ¼ 1   Tps/((1  
/1)(1 f)Tsat). Because Tsat   T0, for given values of Tps, /1, and
f, this critical efﬁcacy is larger than the one based on T0,
implying that the range of drug efﬁcacies required to clear
the latent reservoir and the virus is narrower than under the
assumption that the concentration of T cells remained
constant during the third phase of viral decay. Figure 5
shows how the critical efﬁcacy depends on Tsat. The dotted
line shows one estimate of the drug efﬁcacy for a standard
three drug–therapy regime (1 PI þ 2 RT inhibitors), i.e., e ’
Figure 4. Effect of Ongoing Viral Replication (e , 1) on the Latent
Reservoir, Plasma Viral Load, and the Contribution of Ongoing Viral
Replication to the Level of the Latent Reservoir Measured by the Ratio of
the Rate of Production of Latently Infected Cells by Ongoing Viral
Replication to the Net Removal Rate of Latently Infected Cells
The results were obtained for e values above (e¼0.7 . ec), at (e¼0.1402
¼ ec), and slightly below (e ¼ 0.133 , ec) the critical drug efficacy (ec)
when amin ¼ 0, r ¼  0.00171 d
 1, and x ¼ 0.00939 d
 1.
(A) Latent reservoir.
(B) Plasma viral load.
(C) Contribution of ongoing viral replication.
DOI: 10.1371/journal.pcbi.0020135.g004
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Latent Reservoir Persistence0.7 [51], and the dashdot line shows the critical efﬁcacy at T0.
Clearly, an increase in the T cell concentration may function
to provide more target cells for viral infection, increasing the
extent of ongoing viral replication and thereby requiring a
higher drug efﬁcacy to clear the virus (and also the latent
reservoir). The result also suggests that a slow but continued
increase in CD4
þ T cell counts and the resulting recovery of
immune functions can ironically increase a risk of rapid
ampliﬁcation of viral replication and thereby accelerate
disease progression unless therapy remains effective enough
during the entire time course. It is quite similar to the case of
opportunistic infection that transiently activates the immune
system, enhancing viral replication and thereby replenishing
the latent reservoir unless therapy is 100% effective [53].
Finally, despite an increase in the critical efﬁcacy as T
increases with time on therapy, the critical efﬁcacies for a
clinically relevant range of Tsat remained below an estimate of
the drug efﬁcacy for a standard three drug–therapy regime.
Then why is the elimination of the virus not observed in
patients on standard ART? This apparent contradiction may
be explained as follows. First, the estimate of the efﬁcacy of
standard ART may not be accurate. Louie et al. [51] compared
the relative efﬁcacy of standard ART with a highly potent
four-drug regime and found standard ART to be 68% as
effective as this new regime. Clearly, the four-drug regime
may not be 100% effective. Moreover, drug efﬁcacies are not
constant in time. Dixit et al. [67] by taking into account the
pharmacokinetics of the PI ritonavir estimated that the
efﬁcacy of this drug could vary between 0.4 and 0.85 between
dosing intervals, further complicating estimating the efﬁcacy
of combination ART. Also, in the range of viral loads of
interest in this study (,50 copies/ml), the drug efﬁcacy for
standard therapy may be inﬂuenced by the effects of drug
sanctuaries [19]. If most residual replication is occurring in
such sanctuaries, as has been postulated in some models [19],
then drug efﬁcacy in the sanctuary could be signiﬁcantly
lower than the estimate of 0.7. Hence the actual drug efﬁcacy
may be much closer to, if not below, the critical efﬁcacies
than what was observed in Figure 5. Second, the model
studied in the main text has been simpliﬁed and long-lived
infected cells ignored. If such cells are included in the model
then, as we show in Materials and Methods, the critical
efﬁcacy is increased. Intuitively, this makes sense as drug
therapy now also needs to block infection in this additional
compartment. Third, although we found that for most r
values satisfying r , amin ( 0), the critical efﬁcacy is relatively
insensitive to variations in r or amin, it rapidly approaches 1 as
r closely approaches amin (see Equation 17). Therefore, if the r
values in many HIV-1 patients are closer to their amin values
than in the group of patients considered here (i.e., r   amin ’
 0.00171 d
 1), the corresponding critical efﬁcacies may be
higher than the drug efﬁcacy of standard therapy. Last, even
if standard therapy has e . ec, the time for viral elimination
could be very long under the current standard therapy,
making it appear as if the virus will persist.
Discussion
We have developed a new viral dynamic model that
incorporates the idea that latently infected CD4
þ T cells that
have speciﬁcities for common antigens will be activated more
frequently than latently infected cells with speciﬁcities for
rare antigens. We incorporated this effect by assuming that a,
the rate of latent cell activation, decreases with time on
therapy until it reaches a minimum level, amin. We also took
into consideration the possibility that latently infected cells
could proliferate without becoming activated into virus
production. In Figure 6A we show that under ART this
model gives rise to a rapid ﬁrst-phase viral decay, followed by
a slower ‘‘second-phase’’ decay. Here, however, the second
phase rather than being strictly exponential (i.e., linear on a
log plot) has some curvature. For assays with a lower cutoff of
400–100 copies/ml, as was typical at the time two-phase decay
was deﬁned [6], this second phase would be close to
exponential. However, our model suggests that with assays
that can detect viral load decays to much lower limits, e.g.,
ﬁve copies/ml, curvature should be seen in the viral decay
proﬁle. However, one might speculate that at low plasma viral
loads, i.e., ,50 copies/ml, residual viral replication is
occurring mostly in ‘‘drug sanctuaries’’ [68]. If this were the
case, then the average drug efﬁcacy, e, might be lower than it
was initially, slowing the viral decay at long times. Whether
curvature and possible slowing of viral decay curves occurs at
long times remains to be examined experimentally.
From the model one can also predict the contribution of
long-lived infected cells to plasma virus. Figure 6B shows that
for the parameters we use, long-lived infected cells make a
substantial contribution to plasma virus only during the ﬁrst
few months of therapy, but by the time the viral load decays
below 50 copies/ml their contribution is relatively incon-
sequential. Thus, when focusing on events that occur when
viral loads are below 50 copies/ml, i.e., the third phase of viral
load decay, we simpliﬁed our model by ignoring long-lived
infected cells. How virus and latently infected cells persist
during this third phase was the main focus of our modeling.
Siliciano and colleagues have hypothesized that the long-
term persistence of the HIV-1 latent reservoir may result
Figure 5. Dependency of the Critical Drug Efficacy on the Concentration
of T cells
Tsat represents the concentration that T cells approach as the duration of
ART increases. The solid line shows how the critical efficacy depends on
Tsat. The dotted line indicates a typical drug efficacy estimated for
standard combination ART (e ’ 0.7), and the dashdot line indicates the
critical efficacy when Tsat ¼ T0 ¼ 595 cells/ll, i.e., ec ¼ 0.1402.
DOI: 10.1371/journal.pcbi.0020135.g005
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RNA ,50 copies/ml [37]. Our analysis suggests that if latently
infected cells can undergo occasional bystander proliferation
without transitioning into active viral production, then there
are circumstances under which this hypothesis may be true.
For example, if the net rate of proliferation of latently
infected cells is greater than or equal to their minimum rate
of activation, i.e., r . amin, then the latent reservoir can be
autonomously maintained. Further, if amin . 0, then
continuous activation of latently infected cells will provide
a source of plasma virus even when drug efﬁcacies are
sufﬁciently high (e   ec)t ob l o c km o s to n g o i n gv i r a l
replication. Thus, our modeling shows that there are circum-
stances under which the longevity of the latent reservoir can
be maintained without ongoing virus replication that serves
to continually replenish the latent reservoir.
Viral replication is inevitably accompanied by sequence
evolution, including the selection of drug-resistant mutants.
Therefore, if the stability of the latent reservoir is maintained
primarily by ongoing viral replication (under the condition
that the latent reservoir cannot maintain its stability
autonomously, i.e., r , amin), viral sequences from both the
latent reservoir and plasma virus should rapidly be replaced
by replicating (or recently evolved) plasma virus that may be
genetically distinct from wild-type or archival proviral
genomes generated prior to the initiation of ART. The
replicating plasma virus may also have a greater genetic
distance from the inferred most recent common ancestor,
with possibly a higher ﬁtness in the context of current
therapy, compared with wild-type or archival viruses origi-
nated from the latent reservoir. However, wild-type or
archival viruses have been found to persist in blood plasma
of aviremic patients under ART [22,56–58], arguing against
the possibility that the latent reservoir is stably maintained
solely by ongoing viral replication without any mechanism to
improve its intrinsic stability, such as bystander proliferation.
Recent experimental studies provide more direct evidence
supporting the idea that the latent reservoir stability may
result principally from the intrinsic stability of long-lived
memory CD4
þ T cells. For example, Strain et al. [29] used the
M184V drug resistance mutation in HIV RT as a genetic
marker to identify and track subpopulations of the latent
reservoir replenished by ongoing viral replication during
lamivudine-containing antiviral therapy. They found that
cells infected before treatment initiation, containing the
wild-type HIV-1 DNA, exhibited a much slower decay than
those infected during treatment, deﬁned by the M184V
marker. Thus, the long-lived nature of part of the latent pool
may reﬂect more the stability of immunologic memory,
possibly maintained by bystander proliferation, rather than
its replenishment by ongoing viral replication. A study by
Monie et al. [60,69] further supports this idea of the intrinsic
stability of the latent reservoir. Instead of aviremic patients,
they examined viremic patients who have high levels of viral
replication and immune activation, presumably with a higher
turnover of the latent reservoir than aviremic patients. They
compared HIV-1 pol sequences from stably integrated,
replication-competent viral genomes in the latent reservoir
with actively replicating drug-resistant viruses in the plasma
of patients failing ART. They found that the latent reservoir
dominantly harbored wild-type HIV-1 and archival drug-
resistant viral species despite a ﬁtness disadvantage of these
viruses compared with the contemporaneous plasma viruses,
consistent with the ﬁndings by Strain et al. [29].
Taken together, the intrinsic stability of latently infected
resting memory CD4
þT cells may be of primary importance in
determining their long-term persistence. Although ongoing
viral replication may also affect the stability of the latent
reservoir, the contribution of ongoing viral replication seems
toberelativelyinsigniﬁcant.Further,ongoingviralreplication
alone, independent of the extent of its inﬂuence on the latent
reservoir dynamics, cannot simultaneously explain the ob-
served long-term persistence and genetic composition of the
latentreservoir,highlightingtheroleofnonviralmechanismin
maintaining latent reservoir stability. This suggests that in
many HIV-1 patients the net regeneration rate of the latent
reservoir (r) is maintained comparable to its minimum
activation rate (amin), or much closer to amin than in the group
of patients considered here (r   amin ’  0.00171 d
 1). This
suggestion, of course, needs to be tested experimentally.
Figure 6. Simulated Decay Dynamics of HIV-1 after the Initiation of ART
The initial conditions and parameters used in the simulation are given in
Materials and Methods. The results are shown for three different drug
efficacies (e ¼ 0.3, 0.5, and 0.7).
(A) Viral decay profile.
(B) Contribution of long-lived infected cells to plasma virus (/1(t) ¼
pMM*(t)/( NdT*(t) þ pMM*(t))).
DOI: 10.1371/journal.pcbi.0020135.g006
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If the dynamics of the latent reservoir is dominated by its
intrinsic stability, while the contribution of ongoing viral
replication to the reservoir dynamics is relatively insignif-
icant, this may have signiﬁcant implications for the design of
anti-HIV therapies. To eradicate HIV-1 from patients, it
would then be essential to ﬂush out the latent reservoir
during suppressive antiviral therapy, such as by the activation
of resting memory CD4
þ T cells [70,71] or the selective
expression of HIV-1 from latently infected cells by an agent
such as valproic acid [72]. Otherwise, the intrinsic stability of
the latent reservoir may guarantee lifetime persistence of
HIV-1 since replication-competent HIV-1 recovered from the
latent reservoir is sufﬁcient to rapidly rekindle infection once
therapy is stopped [73]. Further, the above results argue
against an immune modulation strategy intended to reduce
cellular activation and thereby minimize the release of virions
from the latent reservoir [74]. This strategy could be useful
only under the hypothesis that the continuous replenishment
of the latent reservoir by ongoing virus replication is the
principal determinant of the reservoir stability [75]. Early
treatment initiation, such as during primary infection, also
seems to be beneﬁcial in reducing the population size of the
latent reservoir since it is established early in infection [30]
and then may persist autonomously. However, drug toxicity,
cost, and development of resistant mutants, caused by
prolonged treatment periods, are also important factors to
be considered.
Treatments with greater potency (treatment intensiﬁca-
tion) [76,77] will also be required to better control viral
replication, and thereby minimize its contribution to the
stability of the latent reservoir since ongoing viral replication
may still contribute to replenishment of the latent reservoir
in aviremic patients on current ART regimens [26,76] and
even to somewhat higher extents in some cases [29]. It has
been reported that in some chronically infected patients
intensiﬁcation of standard ART accelerates the decay of both
plasma viremia and the latent reservoir, as well as decreases
the frequency of intermittent viremia (blips) [76,77]. More
important, better suppression of viral replication may be a
critical prerequisite for the success of activation-based
strategies, since otherwise the activation of resting memory
CD4
þ T cells may function to boost viral replication by
providing more target cells for viral infection and thereby
could even increase the population size of the latent
reservoir. Further, in this case, the population of latently
infected cells will gradually shift toward cells harboring the
contemporaneous plasma viruses that may have a higher
ﬁtness in the context of current therapy compared with wild-
type or archival viruses dominant in the latent reservoir
population before activation. In parallel with developing
treatments with greater potency, efforts to address the effects
of host factors, such as cellular drug efﬂux proteins, differ-
ential drug metabolism, and drug sanctuary sites, will be
needed since these factors limit antiviral drug efﬁcacy. In
spite of potential beneﬁts, treatment intensiﬁcation (or host
factor control) alone will not be able to eradicate HIV-1 if the
latent reservoir is self-sustaining.
Conclusions
By developing and employing a simple viral dynamic
model, we studied how different viral and host factors may
affect the decay characteristics of the latent reservoir and
plasma virus in HIV-infected patients who initiated treat-
ment during primary infection. We focused on identifying
key factors that enable the stable maintenance of the latent
reservoir and plasma virus at low, but nonzero steady state
l e v e l s .W ei d e n t i ﬁ e dt h r e em ajor factors: 1) bystander
proliferation of latently infected cells, characterized by the
net proliferation rate r, 2) the magnitude of persistent
activation of the latent reservoir, characterized by amin, and
3) the extent of ongoing viral replication, controlled by the
drug efﬁcacy e. We also identiﬁed necessary conditions for
the persistence of both the virus and the latent reservoir. We
found that the bystander proliferation rate of latently
infected cells, r, dominates the dynamics of the latent
reservoir. Further, how much effect variations in r have on
the dynamics of free virus depended on the magnitude of the
minimum activation rate of latently infected cells (amin). For
example, as amin approached zero, any variation in r had little
quantitative or qualitative effect on the dynamics of the virus,
and the persistence of the virus could not be achieved merely
by increasing r when there was little (e . ec) or no ongoing
viral replication. As amin increased, the effect of latent cell
proliferation on the dynamics of the virus became stronger.
Thus, when a certain level of activation of the latent reservoir
was maintained during the entire time course, the viral load
could be stably maintained at a low steady state without
severely depleting the latent reservoir, even without any viral
replication. These results suggest that latent cell activation
can be a major factor inﬂuencing the persistence of the latent
reservoir and the virus. We also found not surprisingly that
the extent of ongoing viral replication (or e) dominates the
dynamics of the virus. Further, when bystander proliferation
was not signiﬁcant, i.e., r , amin, for drug efﬁcacies at or above
the critical efﬁcacy (e   ec), the inﬂuence of ongoing viral
replication on the dynamics of the latent reservoir remained
insigniﬁcant irrespective of the value of amin, and thus the
stable maintenance of the latent reservoir could not be
achieved. However, a decrease in e (increasing viral repli-
cation) below its critical efﬁcacy (ec) can lead to a stable
infected steady state with nonzero levels of the latent
reservoir and the virus.
Finally, we investigated how progressive recovery of T cells
would affect the dynamics of the latent reservoir and the
virus. We found that all the above results remain qualitatively
valid except that bifurcation conditions depend on the
concentration that T cells approach as t ! ‘ (Tsat) instead
of the constant T cell concentration (T0). This result suggests
that the range of drug efﬁcacies required to clear the latent
reservoir and the virus may be much higher than the model
predictions based on the assumption of a constant T cell
concentration, and may contribute to the failure of current
therapies.
Taken together, our results suggest that the persistence of
the latent reservoir and the virus, observed in the vast
majority of HIV patients on suppressive ART, may result
from a combined contribution of intrinsic physiological
parameters of patients, such as r and amin, that characterize
the behavior of latently infected cells, and ongoing viral
replication—the extent of which may also be affected by
patient-dependent drug efﬁcacy and rates of T cell recovery.
The work also clearly raises the issue of the importance of
testing experimentally the fundamental idea of the paper, i.e.,
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bystander proliferation. Such proliferation does not generate
clonal expansion of memory cells, and we suggest that it
might not trigger latently infected cells into active viral
production. If this is the case, then the stability of the latent
reservoir is much easier to understand and our model
provides quantitative testable predictions about the behavior
of this reservoir and plasma viremia below the limits of
detection of standard clinical assays.
Materials and Methods
Eigenvalues of the system. The Jacobian matrix evaluated at the
uninfected steady state ([a ¯, T ¯*, L ¯, V ¯] ¼ [amin, 0, 0, 0]) of the proposed
system (Equations 9–12) is
 x 00 0
0  d amin ð1   fÞð1   eÞkT0
00 r   amin fð1   eÞkT0
0 Nd 0  c
2
6 6 4
3
7 7 5 ð20Þ
The characteristic equation computed from this Jacobian has one
factor of (k1 þ x), indicating that one of the eigenvalues is k1 ¼  x.
The other eigenvalues are the solutions of the characteristic equation
of the following submatrix:
~ A ¼
 d amin ð1   fÞð1   eÞkT0
0 r   amin fð1   eÞkT0
Nd 0  c
2
4
3
5 ð21Þ
Here the characteristic equation is
k
3 þ Bk
2 þ CkþD ¼ 0 ð22Þ
where
B ¼  ð r   aminÞþc þ d
C ¼  ð r   amin þð 1   fÞð1   eÞNkT0Þd  ð r   aminÞc þ dc
D ¼ð ð 1   fÞr   aminÞð1   eÞNkT0d  ð r   aminÞdc
The analytical expressions for the eigenvalues are too complicated
to be presented here. However, in special cases such as amin¼0o re¼
1, the eigenvalues have much simpler forms, as given in Equations 13
and 14, i.e.,
k2 ¼ r; k3;4 ¼þd c
2 6 1
2
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðd þ cÞ
2   4dðc  ð 1   fÞð1   eÞNkT0Þ
q
when amin ¼ 0,
k2 ¼ r   amin;ðwhere amin   0Þ; k3 ¼  c; and k4 ¼  d ðsince c . dÞ
when e ¼ 1.
Generalized bifurcation condition of the system. If amin . 0 (for x
  0), the eigenvalues are too complicated to easily ﬁnd bifurcation
conditions directly from them (unless e ¼ 1). Alternatively, bifurca-
tion conditions can be obtained by ﬁnding conditions to make the
linear system A ˜X ¼ 0 singular, where A ˜ is from Equation 21 and X ¼
[T*, L, V]
T, implying that there exist nontrivial solutions of X as well
as the trivial solution X ¼ 0. For example, the linear system can be
reduced to the following equivalent system by Gaussian elimination:
 d amin ð1   fÞð1   eÞkT0
0 r   amin fð1   eÞkT0
0 Namin  c þð 1   fÞð1   eÞNkT0
2
4
3
5X ¼ 0 ð23Þ
If r¼amin, then only e¼1 can make the system singular, leading to an
inﬁnity of solutions of X.I fr 6¼ amin, then one more step of elementary
row operation yields r((1   f)(1   e)NkT0   c) þ amin(c   (1   e)NkT0)a s
the pivot in this elimination step (or the (3, 3) diagonal element of the
reduced matrix). For this reduced system to be singular, this term
should be equal to zero, yielding the generalized bifurcation
condition as given in Equation 16, i.e.,
rðð1   fÞð1   eÞNkT0   cÞþaminðc  ð 1   eÞNkT0Þ¼0
Note that if e ¼ 1, r should be equal to amin (since c . 0) to satisfy
the singular condition, and thus the bifurcation condition remains
valid for all the e values. Further, when amin ¼ 0, the bifurcation
condition is simpliﬁed to r ¼ 0o rc ¼ (1   f)(1   e)NkT0, and x ¼ 0
simply represents amin ¼ a0 (¼ a), indicating that the bifurcation
condition is valid for all the amin and x values.
Initial conditions. Initial conditions for productively infected cells
(T*) and the activation rate of latently infected cells (a) were chosen
by the following procedure. We assumed that in these patients with
the maximal latent reservoir decay, the latent reservoir steadily
decays, at least on average, from the beginning of the third phase of
viral decay (t ¼ 0 in the model). The same assumption was applied
for viral load, based on the study by Di Mascio et al. [16], where in
three of the ﬁve patients having the greatest degree of viral
suppression with undetectable viral loads, statistically signiﬁcant
viral load decays below 50 copies/ml were observed with a mean
half-life of 6 mo. Here we neglected the effects of transient episodes
of viremia, i.e., viral blips. For the system model to explain the
steady decay of viral load, dV/dt ¼ NdT*   cV   0, implying that T0*
  cV0/Nd. To avoid an abrupt decay of virus at t ¼ 0, we chose the
maximum value of T0*, i.e., T0* ¼ cV0/Nd. To determine a0 ¼ a(0), we
note that dT*/dt ¼ (1   f)(1   e)kT0V þ aL   dT*   0 should be
satisﬁed for viral load to decay steadily in the third phase, implying
that a0   dT0*/L0   (1   f)(1   e)kT0V0/L0 ¼ cV0/NL0   (1   f)(1  
e)kT0V0/L0. We chose the maximum value, i.e., a0 ¼ cV0/NL0   (1  
f)(1   e)kT0V0/L0 (for example, a0 ¼ 0.0058 d
 1 when e ¼ 0.7), in
order to avoid an abrupt decay of T* (and thus V)a tt ¼ 0. Finally,
for the steady decay of the latent reservoir, dL/dt ¼ f(1   e)kT0V þ rL
  aL   0, implying r   a0   f(1   e)kT0V0/L0, providing an upper
bound of r.
Contribution of long-lived cells to bifurcation condition of the
system. The system model (Equations 9–12) can be extended to
include the contribution of long-lived cells as follows:
da=dt ¼  xða   aminÞ
dM =dt ¼ð 1   eÞkMM0V   lMM 
dT =dt ¼ð 1   fÞð1   eÞkT0V þ aL   dT 
dL=dt ¼ fð1   eÞkT0V þ rL   aL
dV=dt ¼ NdT þ pMM   cV ð24Þ
This system has the following uninfected steady state: [a ¯, M ¯*, T ¯*, L ¯,
V ¯] ¼ [amin, 0, 0, 0, 0], and the Jacobian matrix evaluated at this steady
state is
 x 00 0 0
0  lM 00 ð1   eÞkMM0
00  d amin ð1   fÞð1   eÞkT0
000 r   amin fð1   eÞkT0
0 pM Nd 0  c
2
6 6 6 6 4
3
7 7 7 7 5
ð25Þ
One of the eigenvalues of this Jacobian is  x. The other
eigenvalues are the solutions of the characteristic equation of the
following submatrix:
^ A ¼
 lM 00 ð1   eÞkMM0
0  d amin ð1   fÞð1   eÞkT0
00 r   amin fð1   eÞkT0
pM Nd 0  c
2
6 6 4
3
7 7 5 ð26Þ
As explained in the previous section, bifurcation conditions can be
obtained by ﬁnding conditions to make the linear system A ˆX ¼ 0
singular, where X ¼ [M*, T*, L, V]
T. By Gaussian elimination, this
linear system can be reduced to the following equivalent system:
 lM 00 ð1   eÞkMM0
0  d amin ð1   fÞð1   eÞkT0
00 r   amin fð1   eÞkT0
00 NaminlM ð1   eÞpMkMM0 þð ð 1   fÞð1   eÞNkT0   cÞlM
2
6 6 4
3
7 7 5 X¼0
ð27Þ
If r¼amin, then only e¼1 can make the system singular. If r 6¼ amin,
then one more step of elementary row operation yields r((1   f)(1  
e)NkT0 cþ(1 e)pMkMM0/lM) amin((1 e)NkT0 cþ(1 e)pMkMM0/
lM) as the pivot in this elimination step, which should be equal to
zero for this system to be singular. Applying the relation pMkM/lM ¼
/1c/Mps, obtained from the pretreatment quasi–steady state condition
dM*/dt ¼ kMMV   lMM* ¼ 0 and /1 ¼pMMps*/cVps, gives the following
bifurcation condition:
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  aminðð1   eÞNkT0   c þð 1   eÞ/1ðM0=MpsÞcÞ¼0
ð28Þ
which is valid for all the e, amin, and x values. Note that the bifurcation
condition is simpliﬁed to r¼0o rc¼(1 f)(1 e)NkT0þ(1 e)/1(M0/
Mps)c when amin¼0, and r¼amin when e¼1. Finally, from Equation 28,
the critical drug efﬁcacy (ec) becomes
ec ¼ 1  
ðr   aminÞc
ðð1   fÞr   aminÞNkT0 þð r   aminÞ/1ðM0=MpsÞc
ð29Þ
If we apply the pretreatment steady state condition NkTps ¼ (1  
/1)c, with the assumption that (1   f)r   amin ’ r   amin when f ¼ 3 3
10
 6, the critical efﬁcacy is simpliﬁed to
ec ¼ 1  
1
ð1   /1ÞðT0=TpsÞþ/1ðM0=MpsÞ
ð30Þ
Note that the inclusion of long-lived cells in the model increases
the critical efﬁcacy. Intuitively, this makes sense as therapy now needs
to block infection in this additional cellular compartment.
System model and parameters for Figure 6. We applied Equations
24 in the previous section with T0 replaced by Tps to investigate the
decay dynamics of HIV-1 from the initiation of ART. Unless
otherwise speciﬁed, the same pretreatment conditions and parame-
ters given in the main text were applied: Tps¼486 cells/ll, d¼1d
 1, c
¼23 d
 1, N¼2310
4 HIV-1 RNA/cell, f¼3310
 6, /1¼0.05, /2¼0.008
(, 0.01 [6]), r ¼  0.00171 d
 1, x ¼ 0.00939 d
 1, amin ¼ 0, and e ¼ 0.7
(default). For replication-competent latently infected cells and viral
load immediately before the initiation of therapy, Lps ¼ 6 3 10
5 cells
[30,47] and Vps¼10
5 HIV-1 RNA copies/ml were applied, respectively.
The death rate of productively infected long-lived cells (lM) was set to
lM ¼ 0.07 d
 1 [6]. Other pretreatment conditions and parameters of
the model, such as aps, Mps*, Tps*, Mps, k, kM, and pM, were chosen to
satisfy the pretreatment quasi–steady state condition. For example,
the relation Tps*¼(1 /1)cVps/(Nd) can be obtained from dV/dt¼NdT*
þpMM* cV¼0 and /1¼pMMps*/cVps, and aps¼/2dTps*/Lps from /2¼
apsLps/dTps*, respectively. Next, we assumed that a constant fraction of
viral infection events results in chronic infection, i.e., kMMps ¼ akTps,
where a¼0.2 [31] was applied as its baseline value. Then kMMps can be
calculated using k ¼ (1   /1)(1   /2)c/(1   f)NTps from Equation 8.
Finally, Mps* ¼ kMMpsVps/lM can be obtained from dM*/dt ¼ kMMV  
lMM* ¼ 0, and then pM is pM ¼ /1cVps/Mps*.
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